Intravitreal sustained-release steroid implants for the treatment of macular edema following surgical removal of epiretinal membranes

• Verfasst von: Hattenbach, Lars-Olof [VerfasserIn]
• Verfasst von: Springer-Wanner, Christina [VerfasserIn]
• Verfasst von: Hoerauf, Hans [VerfasserIn]
• Verfasst von: Callizo, Josep [VerfasserIn]
• Verfasst von: Jungmann, Stephanie [VerfasserIn]
• Verfasst von: Brauns, Thomas [VerfasserIn]
• Verfasst von: Fulle, Gergana [VerfasserIn]
• Verfasst von: Eichel, Sebastian [VerfasserIn]
• Verfasst von: Koss, Michael Janusz [VerfasserIn]
• Verfasst von: Kuhli-Hattenbach, Claudia [VerfasserIn]
• Titel: Intravitreal sustained-release steroid implants for the treatment of macular edema following surgical removal of epiretinal membranes
• Verf.angabe: Lars-Olof Hattenbach, Christina Springer-Wanner, Hans Hoerauf, Josep Callizo, Stephanie Jungmann, Thomas Brauns, Gergana Fulle, Sebastian Eichel, Michael Janusz Koss, Claudia Kuhli-Hattenbach
• Jahr: 2017
• Umfang: 6 S.
• Fussnoten: Gesehen am 11.09.2018
• Titel Quelle: Enthalten in: Ophthalmologica
• Ort Quelle: Basel : Karger, 1899
• Jahr Quelle: 2017
• Band/Heft Quelle: 237(2017), 4, Seite 232-237
• ISSN Quelle: 1423-0267
• DOI: doi:10.1159/000464259
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1580875394

Abstract

<b><i>Purpose:</i></b> To evaluate the efficacy of intravitreal dexamethasone implant for the treatment of postoperative persistent cystoid macular edema (CME) following macular pucker surgery. <b><i>Methods:</i></b> In this multicenter study, we retrospectively reviewed the data of 37 patients (39 eyes) who had been treated with intravitreal dexamethasone implant (Ozurdex®) for persistent CME following macular pucker surgery. Main outcome measures were change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). <b><i>Results:</i></b> All eyes underwent spectral domain optical coherence tomography examination within 130 days after implantation. We observed a significant decrease in mean CRT from 519.9 to 392.9 µm (<i>p</i> < 0.0001). By this time, mean BCVA had improved from 0.60 to 0.43 logMAR (<i>p</i> = 0.003). Seventeen eyes (43.6%) required at least 1 repeat injection of dexamethasone. Of these, 8 (47%) eyes received a total number of 3 or more dexamethasone injections. <b><i>Conclusion:</i></b> Intravitreal dexamethasone implant injection is an effective treatment option for persistent CME following macular pucker surgery.